Can Pharmacies Bill for Adherence Monitoring?

A pharmacy may have the adherence problem in plain sight: late refills, inconsistent fills, high-risk patients on complex regimens, and no reimbursable way to act on the data in a scalable workflow. That is why the question can pharmacies bill for adherence monitoring matters now. For many pharmacy leaders, the answer is not a simple yes or no. It depends on the care model, the billing entity, the technology in use, and whether adherence data is tied to a recognized reimbursable service.

Can pharmacies bill for adherence monitoring under current rules?

Yes, but not always directly and not under a single universal benefit.

If a pharmacy is asking whether it can generate reimbursement simply for knowing a patient opened a pill container or missed doses, the answer is usually no. Raw adherence tracking by itself is not a standalone billing code in most fee-for-service pharmacy workflows. Payers do not generally reimburse a pharmacy just because adherence was measured.

Where the opportunity becomes real is when adherence monitoring is part of a broader clinical service. In practice, that often means remote therapeutic monitoring, medication therapy management programs, value-based contracts, care management support, or provider-pharmacy collaborations where the data feeds a billable clinical intervention.

This distinction matters. Pharmacies that treat adherence monitoring as a technology feature often stall. Pharmacies that treat it as clinical infrastructure tied to intervention, documentation, and reimbursement are far more likely to create sustainable margin.

Where pharmacies can bill for adherence monitoring

The strongest reimbursement pathway in the current market is usually tied to remote therapeutic monitoring, or RTM. RTM was designed to support the remote monitoring of non-physiologic data, including therapy adherence and response. That is why adherence-focused workflows have drawn so much attention from pharmacies, provider groups, and RPM companies.

But there is a catch. RTM billing is not a blanket right granted to every pharmacy in every state and under every contract. Medicare rules, incident-to structures, scope-of-practice limitations, and payer-specific interpretations all shape whether the pharmacy can bill directly, must partner with a qualified practitioner, or should operate as the technology and service arm behind a physician-led program.

For many pharmacies, the most practical path is collaboration. The pharmacy identifies non-adherence risk, deploys monitoring technology, supports patient engagement, and routes actionable data into a provider workflow that meets billing requirements. In that model, the pharmacy is not just dispensing medication. It is enabling reimbursable therapeutic oversight.

There are also situations where adherence monitoring supports revenue indirectly rather than through a dedicated monitoring claim. Better adherence can improve star performance, refill persistence, medication synchronization success, outcomes-based contract results, and total prescription retention. Those gains are financially meaningful even when the claim line itself sits elsewhere.

Why adherence data alone is not enough

Healthcare organizations do not get paid for passive visibility. They get paid for medically necessary services, documented management, and patient-specific action.

That is the core operational issue. A dashboard full of adherence alerts does not create reimbursement unless someone is responsible for reviewing the data, assessing the patient, documenting the interaction, and escalating when needed. If the technology captures medication access patterns but the workflow stops there, the business case weakens fast.

This is also where many adherence tools fail older adults and Medicare populations. App-based systems, Bluetooth pairing, WiFi setup, and patient training requirements create friction. Friction suppresses engagement. Suppressed engagement leads to bad data. Bad data undermines both care quality and reimbursement integrity.

For adherence monitoring to support billing, the data has to be reliable enough to drive real clinical decisions. That usually means objective, time-stamped medication access data, consistent transmission, patient-specific context, and a workflow that connects non-adherence to intervention.

The operational model that makes billing possible

The pharmacies seeing traction are not asking only, can pharmacies bill for adherence monitoring. They are asking a better question: what service design makes adherence monitoring clinically useful and financially defensible?

That service design usually includes five elements.

First, the patient population must be right. High-risk chronic disease populations, polypharmacy patients, post-discharge patients, pain management populations, and Medicare beneficiaries with documented adherence challenges are more likely to justify monitoring intensity.

Second, the adherence signal must be objective. Refill history helps, but it is delayed and incomplete. Self-report is useful, but unreliable on its own. Real-time medication access data gives the care team a stronger basis for intervention.

Third, the workflow must assign responsibility. Who reviews the data? Who contacts the patient? Who documents therapeutic response, side effects, or barriers? Who escalates to the prescriber? Reimbursement breaks when ownership is vague.

Fourth, the technology must fit the population. If the patient needs a smartphone, an app download, password recovery, and home internet, many pharmacy populations will never get fully onboarded. Simpler deployment increases activation and keeps monitoring programs from collapsing under support burden.

Fifth, the service must be documented in the language of clinical management, not just adherence surveillance. Payers care about management, response, and medical necessity. They do not reward novelty for its own sake.

The real limits pharmacies need to understand

There is money in this category, but there are real limits.

Scope of practice is one. Pharmacies operate under state-specific rules, and pharmacist provider status still varies widely. A pharmacy may be clinically central to the service yet unable to bill in the same way a physician or certain non-physician practitioners can bill.

Payer variability is another. Medicare may create a pathway, but commercial payer adoption can lag or differ. Medicaid rules can vary by state. A program that works financially in one contract may underperform in another.

Technology quality is also a hidden limit. If adherence is inferred from refill dates or self-reported check-ins, the program may not generate the confidence needed for intervention or audit readiness. Objective device-generated medication access data is far more defensible than guesswork.

Then there is labor. If a pharmacy builds a high-touch adherence monitoring service that requires too much manual outreach, margin disappears. The economics improve when automation handles data capture, exception identification, and reporting, while staff focus on patients who truly need intervention.

Why this matters for chronic disease and pain management

Medication behavior is rarely linear. Patients do not simply choose to be adherent or non-adherent. They skip doses when symptoms change, when side effects increase, when cost rises, when cognition declines, or when routines break down.

In chronic pain, for example, medication access patterns can vary by time of day, symptom burden, and patient-specific behavior. Electronic dispensers and response-to-therapy reporting can reveal temporal patterns that are invisible in claims data alone. That matters clinically because the timing of access, not just total use, can signal escalation risk, under-treatment, poor control, or misuse concerns.

It also matters financially. When adherence and response data are captured together, care teams can intervene earlier, document more clearly, and support a stronger case for ongoing remote monitoring services. That is one reason connected adherence platforms are gaining attention across pharmacies, CROs, and provider organizations.

What pharmacy leaders should do next

Do not start with the code. Start with the model.

Ask whether your organization wants direct billing, provider-partner billing, or contract-based value creation. Then test whether your technology and staffing actually support that path. A pharmacy that serves older adults with cardiovascular, diabetes, oncology, or pain populations needs a different operational design than a specialty pharmacy serving digitally fluent patients.

This is also the point where device choice becomes strategic. If the monitoring tool adds setup friction, demands patient behavior change, or creates data gaps, reimbursement potential drops. The best adherence programs remove friction at the point of medication access and make clinical review easier, not harder. That is why some organizations are moving toward cellular, plug-and-play adherence devices that capture objective access data without relying on apps, WiFi, or smartphone ownership.

For pharmacies evaluating the category, the opportunity is real, but only if the service is built to survive actual patient behavior, actual staffing constraints, and actual payer scrutiny. RxKeeper and similar platforms are compelling because they do not treat adherence as a refill metric. They treat it as a reimbursable, monitorable, clinically actionable signal.

The market is moving away from assumption-based adherence and toward proof. Pharmacies that build around measurable medication access, documented intervention, and low-friction deployment will be in a far stronger position than those still waiting for refill history to tell them what already went wrong.

The smarter question is no longer whether adherence matters. It is whether your organization is ready to turn adherence data into care action and billable value before someone else does.